• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.

作者信息

Galgani Simonetta, Prosperini Luca, Haggiag Shalom, Tortorella Carla, Gasperini Claudio

机构信息

MS Centre, Department of Neurosciences, S. Camillo-Forlanini Hospital, c.ne Gianicolense 87, 00152, Rome, Italy.

出版信息

J Neurol. 2018 Sep;265(9):2152-2153. doi: 10.1007/s00415-018-8976-7. Epub 2018 Jul 17.

DOI:10.1007/s00415-018-8976-7
PMID:30019085
Abstract
摘要

相似文献

1
Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.多发性硬化症中阿仑单抗治疗相关的早期短暂无症状性中性粒细胞减少症：一例报告
J Neurol. 2018 Sep;265(9):2152-2153. doi: 10.1007/s00415-018-8976-7. Epub 2018 Jul 17.
2
Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.在接受阿仑单抗输注 23 天后，一位多发性硬化症患者出现中性粒细胞减少伴致命结局。
Mult Scler Relat Disord. 2018 Jul;23:15-16. doi: 10.1016/j.msard.2018.04.014. Epub 2018 Apr 28.
3
Acute leukocytosis during alemtuzumab treatment in patients with active relapsing-remitting multiple sclerosis.在接受活性复发缓解型多发性硬化症治疗的患者中，在用阿仑单抗治疗期间出现的急性白细胞增多症。
Mult Scler Relat Disord. 2019 Feb;28:98-100. doi: 10.1016/j.msard.2018.12.024. Epub 2018 Dec 18.
4
Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.两例接受阿仑单抗治疗多发性硬化症后发生的1型糖尿病：另一种可能的继发性自身免疫性疾病。
J Neurol. 2019 May;266(5):1270-1271. doi: 10.1007/s00415-019-09257-5. Epub 2019 Feb 25.
5
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.与阿仑单抗输注相关的急性冠状动脉综合征在多发性硬化症中的情况
Neurology. 2018 May 1;90(18):852-854. doi: 10.1212/WNL.0000000000005417. Epub 2018 Mar 30.
6
Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.监测和管理接受阿仑单抗治疗的多发性硬化症患者的自身免疫：实用建议。
J Neurol. 2018 Nov;265(11):2494-2505. doi: 10.1007/s00415-018-8822-y. Epub 2018 Mar 10.
7
Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.与复发性多发性硬化症初始阿仑单抗输注周期相关的急性心肌梗死。
Mult Scler Relat Disord. 2019 Sep;34:100-102. doi: 10.1016/j.msard.2019.06.022. Epub 2019 Jun 18.
8
[The use of alemtuzumab after non-selective immunosuppression in a patient with highly active rapidly progressive remitting multiple sclerosis].
Zh Nevrol Psikhiatr Im S S Korsakova. 2019;119(2. Vyp. 2):116-120. doi: 10.17116/jnevro201911922116.
9
Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.阿仑单抗治疗多发性硬化症后出现复发性和普遍性斑秃：一种继发性自身免疫性疾病。
Mult Scler Relat Disord. 2019 Jan;27:406-408. doi: 10.1016/j.msard.2018.12.005. Epub 2018 Dec 3.
10
Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.2例接受阿仑单抗治疗的多发性硬化患者发生噬血细胞性淋巴组织细胞增生症。
Neurology. 2018 May 1;90(18):849-851. doi: 10.1212/WNL.0000000000005420. Epub 2018 Mar 30.

引用本文的文献

1
Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series.疾病修饰疗法与血液系统疾病：病例报告和病例系列的系统评价
Front Neurol. 2024 Jun 18;15:1386527. doi: 10.3389/fneur.2024.1386527. eCollection 2024.
2
State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies.特异质性药物诱导的中性粒细胞减少症或粒细胞缺乏症的研究现状，重点关注生物疗法。
J Clin Med. 2019 Sep 1;8(9):1351. doi: 10.3390/jcm8091351.
3
Vitamin D supplementation for the prevention or depletion of side effects of therapy with alemtuzumab in multiple sclerosis.

本文引用的文献

1
Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion.在接受阿仑单抗输注 23 天后，一位多发性硬化症患者出现中性粒细胞减少伴致命结局。
Mult Scler Relat Disord. 2018 Jul;23:15-16. doi: 10.1016/j.msard.2018.04.014. Epub 2018 Apr 28.
2
Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment.显著但罕见：阿仑单抗治疗多发性硬化症后出现中性粒细胞减少症。
Mult Scler Relat Disord. 2017 Nov;18:181-183. doi: 10.1016/j.msard.2017.09.028. Epub 2017 Sep 25.
3
Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
补充维生素D以预防或减轻阿仑单抗治疗多发性硬化症的副作用。
Ther Clin Risk Manag. 2019 Jul 12;15:891-904. doi: 10.2147/TCRM.S188941. eCollection 2019.
4
A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytes.1例阿仑单抗诱发的多发性硬化症中性粒细胞减少症伴大颗粒淋巴细胞增多。
BMC Neurol. 2018 Oct 29;18(1):178. doi: 10.1186/s12883-018-1183-4.
用阿仑单抗治疗的多发性硬化症患者的中性粒细胞减少症
JAMA Neurol. 2017 Sep 1;74(9):1143-1144. doi: 10.1001/jamaneurol.2017.1456.
4
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.阿仑单抗与干扰素β1a 作为复发缓解型多发性硬化症一线治疗的比较：一项随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.
5
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.阿仑单抗治疗缓解复发型多发性硬化症患者：一项疾病修饰治疗后随机对照 3 期试验。
Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.
6
Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab.中性粒细胞表达CD52，并在存在阿仑单抗的情况下表现出补体介导的溶解作用。
Blood. 2009 Oct 1;114(14):3052-5. doi: 10.1182/blood-2009-02-203075. Epub 2009 Jul 28.
7
Strategies in the management of alemtuzumab-related side effects.阿仑单抗相关副作用的管理策略。
Semin Oncol. 2006 Apr;33(2 Suppl 5):S29-35. doi: 10.1053/j.seminoncol.2006.01.027.
8
Recognition of CD52 allelic gene products by CAMPATH-1H antibodies.CAMPATH-1H抗体对CD52等位基因产物的识别。
Immunology. 1996 Jun;88(2):183-90. doi: 10.1111/j.1365-2567.1996.tb00003.x.